IFNG and non-small cell lung carcinoma: Even though interferon-γ (IFN-γ) was not significantly differently expressed in matched patient samples (p = 0.1774, paired t-test with controlling FDR at q = 0.05), we included this cytokine in the analysis based on a recent publication by Higgs et al. [23] They found that survival of NSCLC patients receiving durvalumab correlated with detectable IFN-γ mRNA in tumor biopsies.